I think you are way of the mark Hedgehog-these are only computer generated figures. Look at previous RNS's-all good news. Although last years results won't be brilliant (due to reorganisation costs after reverse takeover) the future from september 14 on looks very positive and I expect results will spark a rerating.
As my previous post this latest RNS of contract valued £2.5 million on top of others announced this year seems to have been missed by the market which now makes IXICO an outstanding buy. Less its cash pile the company is only valued at about £2 million and will be in profit next year. Should be at least double on this news.
Ixico has dropped to a low for the year at 35p and in my view is due for a big bounce. The company is one of two on the market involved in Dementia diagnosis and has recently launched a dimentia diagnostic kit which it is promoting. With the immense focus on this disease by the government this could turn into really big business Directors were recently granted options at 49p with the ability to take these up subject to increasing the share price from 49p. The company has been doing very well lately too. An update is due from the company in December Cash in the bank of over £3 million and company valued at only £5.25 million inc cash this has got to be a steal.
I bought in end last year on news of collaboration with Chinese re: dementure. A massive problem in China, as elsewhere. Paid 42p and within a few days was well over a pound. Top sliced 50% to get investment back plus some. Happy to hold the freeby shares, but it's going to be a looong wait. I'm sure it is doing all it can on research but will need a breakthrough on drugs, and if approved, no limit to how far sp can go. In MHO
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.